Trump Named as Defendant in New Lawsuit Challenging Cannabis Rescheduling

President Donald Trump is among the defendants in a new federal lawsuit challenging the administration's decision to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act.

The complaint, filed by a coalition including anti-cannabis activists, substance abuse treatment professionals, physicians, and a cannabis-focused biopharmaceutical company, alleges the Drug Enforcement Administration violated federal rulemaking procedures when it finalized the rescheduling order.

According to the filing, the "Final Order was issued without prior notice-and-comment" as required under the Administrative Procedure Act. The plaintiffs argue they are "aggrieved" parties who will suffer direct harm from marijuana's new Schedule III classification.

An Unusual Alliance

The plaintiff coalition represents an uncommon mix of interests united in opposition to rescheduling. Traditional anti-marijuana advocacy groups have joined forces with medical professionals who treat substance use disorders and, notably, a biopharmaceutical corporation with cannabis-related products.

This marks at least the third major legal challenge to the rescheduling decision since the administration moved forward with the policy change earlier this year. Previous lawsuits have come from state attorneys general and industry stakeholders, but this case stands out for naming Trump personally as a defendant alongside DEA Administrator and Attorney General officials.

The pharmaceutical company's involvement raises questions about competitive concerns in the cannabis market. Schedule III classification would maintain certain federal restrictions while opening new research pathways and tax benefits for state-licensed cannabis businesses under Section 280E of the tax code.

The Procedural Argument

The lawsuit centers on claims that DEA bypassed required public comment periods before implementing the schedule change. Federal agencies typically must publish proposed rules in the Federal Register and allow time for public input before finalizing major regulatory decisions.

Plaintiffs argue this procedural failure violated their rights to participate in the rulemaking process and that the agency lacked sufficient scientific evidence to support rescheduling. They contend marijuana's current accepted medical use and abuse potential don't meet the criteria for Schedule III substances.

"These procedural requirements exist precisely to prevent arbitrary agency action," said one attorney familiar with administrative law challenges, though not involved in this case. "If the plaintiffs can prove DEA skipped required steps, they may have grounds regardless of the underlying policy merits."

What's At Stake

The lawsuit could potentially delay or reverse the rescheduling decision, affecting billions of dollars in cannabis commerce. State-licensed operators have anticipated significant tax relief under Schedule III, as the change would allow them to deduct normal business expenses currently prohibited under 280E.

Research institutions have also prepared to expand cannabis studies under the less restrictive scheduling tier. A reversal would maintain existing barriers to federal research grants and clinical trials.

For the pharmaceutical plaintiffs, the stakes may involve competitive positioning as cannabis products gain legitimacy in medical contexts. Schedule III status could accelerate development of cannabis-derived medications while creating regulatory uncertainty for companies with existing drug approval pathways.

Legal Timeline Unclear

The case will likely proceed through federal district court before any potential appeals. Similar administrative law challenges can take months or years to resolve, though plaintiffs may seek preliminary injunctions to halt implementation while litigation continues.

DEA and Justice Department attorneys will need to defend both the substance of the rescheduling decision and the procedures used to implement it. The administration has not yet filed a formal response to the complaint.

Legal experts note that courts generally defer to agency expertise on scientific and technical matters, but procedural violations can provide grounds for overturning agency actions even when the underlying policy might otherwise survive scrutiny.

The lawsuit adds another layer of uncertainty to an already complex federal cannabis policy landscape as states continue expanding legal markets and Congress debates broader reform legislation.

---

This article is based on original reporting by www.marijuanamoment.net.